MX9702853A - Metodos para inhibir condiciones asociadas con el neuropeptido "y". - Google Patents

Metodos para inhibir condiciones asociadas con el neuropeptido "y".

Info

Publication number
MX9702853A
MX9702853A MX9702853A MX9702853A MX9702853A MX 9702853 A MX9702853 A MX 9702853A MX 9702853 A MX9702853 A MX 9702853A MX 9702853 A MX9702853 A MX 9702853A MX 9702853 A MX9702853 A MX 9702853A
Authority
MX
Mexico
Prior art keywords
neuropeptide
methods
conditions associated
inhibiting conditions
inhibiting
Prior art date
Application number
MX9702853A
Other languages
English (en)
Other versions
MXPA97002853A (es
Inventor
Robert Frederick Bruns Jr
Donald Richard Gehlert
James Jeffry Howbert
William Henry Walker Lunn
Original Assignee
Lilly Co Eli
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lilly Co Eli filed Critical Lilly Co Eli
Publication of MX9702853A publication Critical patent/MX9702853A/es
Publication of MXPA97002853A publication Critical patent/MXPA97002853A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

Se proporciona un método para inhibir un trastorno fisiologico asociado con un exceso de neuropéptido y o sus síntomas, que comprende administrar a un humano en necesidad del mismo una cantidad efectiva de un compuesto que tiene la formula (I) en la que R1 y R3 son independientemente hidrogeno, -CH3 (a) o (b), en el que Ar es fenilo opcionalmente sustituido, R2 se selecciona del grupo que consiste de pirrolidina, hexametilenimino y piperidino; o una sal o solvato farmacéuticamente aceptable del mismo.
MXPA/A/1997/002853A 1994-10-20 1997-04-18 Metodos para inhibir condiciones asociadas con el neuropeptido y MXPA97002853A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US08/326,675 US6562862B1 (en) 1994-10-20 1994-10-20 Methods of inhibiting physiological conditions associated with an excess of neuropeptide Y
US08326675 1994-10-20
PCT/US1995/013246 WO1996012490A1 (en) 1994-10-20 1995-10-19 Methods of inhibiting conditions associated with neuropeptide y

Publications (2)

Publication Number Publication Date
MX9702853A true MX9702853A (es) 1997-07-31
MXPA97002853A MXPA97002853A (es) 1997-12-01

Family

ID=

Also Published As

Publication number Publication date
NO971520L (no) 1997-04-03
NZ295575A (en) 2000-06-23
FI971635A0 (fi) 1997-04-17
US5576337A (en) 1996-11-19
CA2200990A1 (en) 1996-05-02
ZA958800B (en) 1997-04-18
CZ115997A3 (en) 1997-10-15
US5567714A (en) 1996-10-22
US5567715A (en) 1996-10-22
AU3895595A (en) 1996-05-15
EP0785785A4 (en) 1998-11-11
US6562862B1 (en) 2003-05-13
IL115663A0 (en) 1996-01-19
HUT76852A (en) 1997-12-29
CZ287411B6 (en) 2000-11-15
FI971635A (fi) 1997-04-17
KR970706818A (ko) 1997-12-01
CN1160998A (zh) 1997-10-01
RU2188015C2 (ru) 2002-08-27
WO1996012490A1 (en) 1996-05-02
IL115663A (en) 1999-08-17
NO971520D0 (no) 1997-04-03
US5504094A (en) 1996-04-02
EP0785785A1 (en) 1997-07-30
JPH10507757A (ja) 1998-07-28
UA46744C2 (uk) 2002-06-17
AU689664B2 (en) 1998-04-02
CN1091598C (zh) 2002-10-02
TW410156B (en) 2000-11-01
MY132056A (en) 2007-09-28

Similar Documents

Publication Publication Date Title
MY132056A (en) Methods of inhibiting physiological conditions associated with an excess of neuropeptide y.
MX9701329A (es) Metodos para la inhibicion de la replicacion viral.
IL112048A0 (en) Methods of inhibiting thrombin
MX9701325A (es) Metodos para inhibir la mucositis ulcerativa.
MX9701360A (es) Metodos para la inhibicion de la desmielinizacion y las enfermedades de la dismielinizacion.
PH31261A (en) Methods for inhibiting endometriosis.
DE69430465D1 (de) Hemmung uteriner Fibrose
MY112973A (en) Methods for inhibiting vascular smooth muscle cell migration
MX9701334A (es) Metodos para inhibir la degeneracion de protesis oseas.
MX9709466A (es) Medicamento para inhibir el melanoma.
EA199700136A1 (ru) Способы ингибирования экзогенных эстрогенов
MX9701333A (es) Metodos para inhibir el daño neuronal.
MY113406A (en) Methods of inhibiting physiological conditions associated with an excess of bradykinin
MX9702148A (es) Metodos para inhibir la mitosis endometrial.
MX9701327A (es) Metodos para inhibir el cancer endometrial.
MX9701359A (es) Metodos para la inhibicion de la hiperplasia endometrial primaria.
MX9701331A (es) Metodos para mantener los dientes y los huesos bucales.
MX9701328A (es) Metodos de reduccion de la cicatrizacion en la curacion de heridas.
MX9705940A (es) Metodos y composiciones para inhibir los efectos de la interleucina 6.
MX9705215A (es) Uso de 2-fenil-3-aroilbenzotiofenos para inhibir los efectos de la hormona del crecimiento.
MX9705697A (es) Metodos para reducir los niveles de calcio del suero.
MX9709536A (es) Metodo para reducir el factor de transcripcion bef-1.
MX9706072A (es) Metodos de inhibicion de la adhesion celula-celula.
MX9706520A (es) Metodos para inhibir el cancer de ovario.
MX9709651A (es) Metodos para modulacion del factor de transcripcion nf-kb.

Legal Events

Date Code Title Description
FG Grant or registration
MM Annulment or lapse due to non-payment of fees